Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family Members

DOI: 10.1161/circgenetics.114.001003
Circulation: Cardiovascular Genetics, 2015, 8, 437-46.

#	Paper	IF	Citations
322	Arrhythmogenic right ventricular dysplasia/cardiomyopathy-three decades of progress. **2015**, 79, 901-13		37
321	Left Ventricular Involvement in ARVD/C: Is It Time to Readjust Our Views?. **2015**, 8, 1311-2		4
320	Arrhythmogenic Right Ventricular Cardiomyopathy: Toward a Modern Clinical and Genomic Understanding. *Circulation: Cardiovascular Genetics*, **2015**, 8, 421-4		6
319	The Value of Cardiac Magnetic Resonance Imaging in Evaluation of Pediatric Patients for Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. **2015**, 66, 873-874		7
318	Reply: The Value of Cardiac Magnetic Resonance Imaging in Evaluation of Pediatric Patients for Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. **2015**, 66, 874-875		
317	Arrhythmogenic Right Ventricular Dysplasia in Neuromuscular Disorders. **2016**, 10, 173-180		4
316	Clinical Presentation and Outcomes by Sex in Arrhythmogenic Right Ventricular Cardiomyopathy: Findings from the North American ARVC Registry. **2016**, 27, 555-62		26
315	Fetal arrhythmogenic right ventricular cardiomyopathy with double mutations in TMEM43. **2016**, 58, 409-411		7
314	Arrhythmogenic right-ventricular cardiomyopathy: molecular genetics into clinical practice in the era of next generation sequencing. **2016**, 17, 399-407		14
313	Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. **2016**, 102, 303-12		35
312	Further Progress in Predicting Life-Threatening Arrhythmias in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy. **2016**, 68, 2551-2553		1
311	Arrhythmogenic Right Ventricular Cardiomyopathy: Clinical Course and Predictors of Arrhythmic Risk. **2016**, 68, 2540-2550		99
310	Genetics and Genomics of Single-Gene Cardiovascular Diseases: Common Hereditary Cardiomyopathies as Prototypes of Single-Gene Disorders. **2016**, 68, 2831-2849		31
309	The genetic background of arrhythmogenic right ventricular cardiomyopathy. **2016**, 32, 398-403		36
308	Arrhythmogenic right ventricular cardiomyopathy: implications of next-generation sequencing in appropriate diagnosis. **2017**, 19, 1063-1069		25
307	The ventricular ectopic QRS interval for diagnosis and risk stratification in arrhythmogenic right ventricular dysplasia/cardiomyopathy: Is this the answer?. **2016**, 13, 1513-4		
306	Cardiac Fibro-Adipocyte Progenitors Express Desmosome Proteins and Preferentially Differentiate to Adipocytes Upon Deletion of the Desmoplakin Gene. **2016**, 119, 41-54		57

305	Advances in the Diagnosis and Management of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. **2016**, 18, 53	9
304	Clinical characterisation and risk stratification of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy 50 years of age. **2016**, 24, 740-747	5
303	A 43-Year-Old Man With Daytime Sleepiness and a Heart Murmur. **2016**, 150, e117-e120	
302	Men and Women in Arrhythmogenic Right Ventricular Cardiomyopathy. **2016**, 2, 556-557	1
301	Right Ventricular Imaging and Computer Simulation for Electromechanical Substrate Characterization in Arrhythmogenic Right Ventricular Cardiomyopathy. **2016**, 68, 2185-2197	33
300	The Canadian Arrhythmogenic Right Ventricular Cardiomyopathy Registry: Rationale, Design, and Preliminary Recruitment. **2016**, 32, 1396-1401	4
299	Long-term right ventricular implantable cardioverter-defibrillator lead performance in arrhythmogenic right ventricular cardiomyopathy. **2016**, 13, 1964-70	9
298	Catecholaminergic Polymorphic Ventricular Tachycardia: Activity as Tolerated?. **2016**, 2, 263-265	
297	2015 update on the diagnosis and management of arrhythmogenic right ventricular cardiomyopathy. **2016**, 31, 46-56	20
296	Recent advances in genetic testing and counseling for inherited arrhythmias. **2016**, 32, 389-397	24
295	Arrhythmogenic cardiomyopathy. **2016**, 11, 33	80
294	Mapping and ablation procedures for the treatment of ventricular tachycardia. **2016**, 14, 1071-87	2
293	Right ventricular strain by MR quantitatively identifies regional dysfunction in patients with arrhythmogenic right ventricular cardiomyopathy. **2016**, 43, 1132-9	31
292	Arrhythmogenic right ventricular dysplasia/cardiomyopathy: arrhythmogenesis in the apparently normal heart?. **2016**, 18, 953-4	1
291	Exercise and Inherited Arrhythmias. **2016**, 32, 452-8	14
290	Myocardial expression profiles of candidate molecules in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia compared to those with dilated cardiomyopathy and healthy controls. **2016**, 13, 731-41	23
289	Evidence Mounts That Severity of Disease Impacts the Prognosis for Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. **2016**, 2, 116-117	
288	Next generation sequencing-based copy number analysis reveals low prevalence of deletions and duplications in 46 genes associated with genetic cardiomyopathies. **2016**, 4, 143-51	27

287	Safety of American Heart Association-recommended minimum exercise for desmosomal mutation carriers. **2016**, 13, 199-207	54
286	Approach to family screening in arrhythmogenic right ventricular dysplasia/cardiomyopathy. **2016**, 37, 755-63	56
285	Comprehensive multi-modality imaging approach in arrhythmogenic cardiomyopathy-an expert consensus document of the European Association of Cardiovascular Imaging. **2017**, 18, 237-253	88
284	Multilevel analyses of SCN5A mutations in arrhythmogenic right ventricular dysplasia/cardiomyopathy suggest non-canonical mechanisms for disease pathogenesis. **2017**, 113, 102-111	111
283	Arrhythmogenic right ventricular dysplasia/cardiomyopathy. **2017**, 27, S57-S61	4
282	Genotype-phenotype relationship in patients with arrhythmogenic right ventricular cardiomyopathy caused by desmosomal gene mutations: A systematic review and meta-analysis. **2017**, 7, 41387	28
281	Potential new mechanisms of pro-arrhythmia in arrhythmogenic cardiomyopathy: focus on calcium sensitive pathways. **2017**, 25, 157-169	25
280	Editorial commentary: Wolff-Parkinson-White pattern and syndrome: Where do we stand in 2017?. **2017**, 27, 269-270	
279	Identification of Cadherin 2 () Mutations in Arrhythmogenic Right Ventricular Cardiomyopathy. *Circulation: Cardiovascular Genetics*, **2017**, 10,	94
278	At the Heart of the Pregnancy: What Prenatal and Cardiovascular Genetic Counselors Need to Know about Maternal Heart Disease. **2017**, 26, 669-688	3
277	Comparison of Features of Fatal Versus Nonfatal Cardiac Arrest in Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. **2017**, 120, 111-117	24
276	Electronic health record phenotype in subjects with genetic variants associated with arrhythmogenic right ventricular cardiomyopathy: a study of 30,716 subjects with exome sequencing. **2017**, 19, 1245-1252	33
275	Characterization of the arrhythmogenic substrate in patients with arrhythmogenic right ventricular cardiomyopathy undergoing ventricular tachycardia ablation. **2017**, 19, 1049-1062	24
274	Distinct fibrosis pattern in desmosomal and phospholamban mutation carriers in hereditary cardiomyopathies. **2017**, 14, 1024-1032	39
273	Whole exome sequencing with genomic triangulation implicates CDH2-encoded N-cadherin as a novel pathogenic substrate for arrhythmogenic cardiomyopathy. **2017**, 12, 226-235	35
272	Arrhythmogenic Right Ventricular Cardiomyopathy. **2017**, 376, 61-72	302
271	Arrhythmogenic cardiomyopathy: pathology, genetics, and concepts in pathogenesis. **2017**, 113, 1521-1531	58
270	Unique genetic background and outcome of non-Caucasian Japanese probands with arrhythmogenic right ventricular dysplasia/cardiomyopathy. **2017**, 5, 639-651	10

269	Arrhythmogenic Cardiomyopathy. **2017**, 121, 784-802	167
268	: A qualitative study of psychological sequelae to the implantable cardioverter defibrillator as a treatment for the prevention of sudden cardiac death in arrhythmogenic right ventricular cardiomyopathy.. **2017**, 6, 2048004017698614	
267	Heart Failure Is Common and Under-Recognized in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. **2017**, 10,	38
266	Plakophilin-2 is required for transcription of genes that control calcium cycling and cardiac rhythm. **2017**, 8, 106	94
265	Analysis of 60 706 Exomes Questions the Role of De Novo Variants Previously Implicated in Cardiac Disease. *Circulation: Cardiovascular Genetics*, **2017**, 10,	3
264	Sudden Cardiac Death in Genetic Cardiomyopathies. **2017**, 9, 581-603	10
263	A Novel Mutation in Junctional Plakoglobin Causing Lethal Congenital Epidermolysis Bullosa. **2017**, 191, 266-269.e1	4
262	Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy. **2017**, 136, 2068-2082	100
261	Miocardiopat□s III. Miocardiopat□ restrictiva. Displasia arritmog□ica del ventr□ulo derecho. Miocardiopat□ no compactada. **2017**, 12, 2573-2584	
260	Genetic testing in cardiomyopathies: an update on indications and benefits. **2017**, 32, 189-195	3
259	Combination of ECG and Echocardiography for Identification of Arrhythmic Events in Early ARVC. **2017**, 10, 503-513	45
258	Moving From Multimodality Diagnostic Tests Toward Multimodality Risk Stratification in ARVC. **2017**, 10, 514-517	1
257	Minding the Genes: a Multidisciplinary Approach towards Genetic Assessment of Cardiovascular Disease. **2017**, 26, 224-231	14
256	High proportion of genetic cases in patients with advanced cardiomyopathy including a novel homozygous Plakophilin 2-gene mutation. **2017**, 12, e0189489	20
255	Sudden cardiac death: focus on the genetics of channelopathies and cardiomyopathies. **2017**, 24, 56	17
254	Performance of the 2015 International Task Force Consensus Statement Risk Stratification Algorithm for Implantable Cardioverter-Defibrillator Placement in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. **2018**, 11, e005593	8
253	Arrhythmic Risk Stratification for Arrhythmogenic Right Ventricular Cardiomyopathy: Should We Ask Who Is at High Risk or Who Is at Low Risk?. **2018**, 11, e006160	
252	Sequencing of Linkage Region on Chromosome 12p11 Identifies as a Candidate Gene for Left Ventricular Mass in Dominican Families. **2018**, 8, 659-668	2

251	Isolated, premature ventricular complex-induced right ventricular dysfunction mimicking arrhythmogenic right ventricular cardiomyopathy. **2018**, 4, 222-226	2
250	Controversies in Brugada syndrome. **2018**, 28, 284-292	5
249	Whole-Exome Sequencing Reveals and Mutations as a Potential Digenic Cause of Left Ventricular Noncompaction. **2018**, 11, e001966	4
248	Identification of sarcomeric variants in probands with a clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC). **2018**, 29, 1004-1009	10
247	Arrhythmogenic right ventricular cardiomyopathy. **2018**, 34, 356-368	4
246	Epidemiology and Clinical Aspects of Genetic Cardiomyopathies. **2018**, 14, 119-128	22
245	Genetic Evaluation of Cardiomyopathy-A Heart Failure Society of America Practice Guideline. **2018**, 24, 281-302	160
244	Controversies Surrounding Exercise in Genetic Cardiomyopathies. **2018**, 14, 189-200	1
243	Genetic basis of arrhythmogenic cardiomyopathy. **2018**, 33, 276-281	14
242	Clinical genetic testing in pediatric cardiomyopathy: Is bigger better?. **2018**, 93, 33-40	26
241	Lifelong arrhythmic risk stratification in arrhythmogenic right ventricular cardiomyopathy: distribution of events and impact of periodical reassessment. **2018**, 20, f20-f29	9
240	Heart transplantation in arrhythmogenic right ventricular cardiomyopathy - Experience from the Nordic ARVC Registry. **2018**, 250, 201-206	14
239	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. **2018**, 15, e190-e252	264
238	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. **2018**, [illegible]	151
237	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. **2018**, 72, 1677-1749	180
236	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. **2018**, 138, e210-e271	173
235	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. **2018**, 138, e272-e391	307
234	Ventricular Arrhythmias in Heart Failure. **2018**, 858-869	

233	Ventricular tachycardia ablation in arrhythmogenic right ventricular cardiomyopathy patients with TMEM43 gene mutations. **2018**, 29, 90-97	6
232	Arrhythmogenic right ventricular dysplasia/cardiomyopathy: an electrocardiogram-based review. **2018**, 20, f3-f12	16
231	Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. **2018**, 192-204	
230	Blockade of the Adenosine 2A Receptor Mitigates the Cardiomyopathy Induced by Loss of Plakophilin-2 Expression. **2018**, 9, 1750	7
229	Bioinformatic analysis of a plakophilin-2-dependent transcription network: implications for the mechanisms of arrhythmogenic right ventricular cardiomyopathy in humans and in boxer dogs. **2018**, 20, iii125-iii132	9
228	OBSOLETE: Arrhythmogenic Right Ventricular Cardiomyopathy. **2018**,	
227	OBSOLETE: Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. **2018**,	1
226	Pleiotropic Phenotypes Associated With PKP2 Variants. **2018**, 5, 184	10
225	Catheter Ablation of Ventricular Tachycardia in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. **2018**, 48, 890-905	2
224	Electrocardiographic Features Differentiating Arrhythmogenic Right Ventricular Cardiomyopathy From an Athlete's Heart. **2018**, 4, 1613-1625	9
223	Additional Genetic Variants in Inherited Dilated Cardiomyopathy: Just Another Brick in the Wall?. **2018**, 11, e002249	1
222	Managing Secondary Genomic Findings Associated With Arrhythmogenic Right Ventricular Cardiomyopathy: Case Studies and Proposal for Clinical Surveillance. **2018**, 11, e002237	11
221	No major role for rare plectin variants in arrhythmogenic right ventricular cardiomyopathy. **2018**, 13, e0203078	2
220	Frequency of genetic variants associated with arrhythmogenic right ventricular cardiomyopathy in the genome aggregation database. **2018**, 26, 1312-1318	20
219	Arrhythmogenic Right Ventricular Cardiomyopathy. **2018**, 182-191	
218	Arrhythmogenic Right Ventricular Cardiomyopathy. **2018**, 291-296	
217	Right ventricular dysplasia: management and treatment in light of current evidence. **2018**, 8, 101-106	1
216	Clinical Diagnosis, Imaging, and Genetics of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: JACC State-of-the-Art Review. **2018**, 72, 784-804	105

215	Prediction of Life-Threatening Ventricular Arrhythmia in Patients With Arrhythmogenic Cardiomyopathy: A Primary Prevention Cohort Study. **2018**, 11, 1377-1386	37
214	Primary prevention implantable cardioverter-defibrillator and opportunities for sudden cardiac death risk assessment in non-ischaemic cardiomyopathy. **2018**, 39, 2859-2866	20
213	Absence of a primary role for TTN missense variants in arrhythmogenic cardiomyopathy: From a clinical and pathological perspective. **2018**, 41, 615-622	5
212	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. **2018**, 72, e91-e220	411
211	Atrial involvement in arrhythmogenic right ventricular cardiomyopathy patients referred for ventricular arrhythmias ablation. **2018**, 29, 1388-1395	3
210	Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). **2018**, 20, 899-909	96
209	Arrhythmic outcome of arrhythmogenic right ventricular cardiomyopathy patients without implantable defibrillators. **2018**, 29, 1396-1402	7
208	Impact of Exercise Restriction on Arrhythmic Risk Among Patients With Arrhythmogenic Right Ventricular Cardiomyopathy. **2018**, 7,	37
207	Prevention of Sudden Cardiac Death in Arrhythmogenic Cardiomyopathy. **2018**, 4, 769-770	0
206	A founder homozygous DSG2 variant in East Asia results in ARVC with full penetrance and heart failure phenotype. **2019**, 274, 263-270	17
205	Arrhythmogenic Right Ventricular Cardiomyopathy: A Review of Living and Deceased Probands. **2019**, 28, 1034-1041	4
204	Beyond the One Gene-One Disease Paradigm: Complex Genetics and Pleiotropy in Inheritable Cardiac Disorders. **2019**, 140, 595-610	56
203	For Whom the Bell Tolls : Refining Risk Assessment for Sudden Cardiac Death. **2019**, 21, 106	3
202	Disruption of Ca Homeostasis and Connexin 43 Hemichannel Function in the Right Ventricle Precedes Overt Arrhythmogenic Cardiomyopathy in Plakophilin-2-Deficient Mice. **2019**, 140, 1015-1030	46
201	Phenotypic Manifestations of Arrhythmogenic Cardiomyopathy in Children and Adolescents. **2019**, 74, 346-358	31
200	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. **2019**, 16, e373-e407	73
199	Plakophilin-2 Haploinsufficiency Causes Calcium Handling Deficits and Modulates the Cardiac Response Towards Stress. **2019**, 20,	23
198	Arrhythmogenic Right Ventricular Cardiomyopathy-Associated Desmosomal Variants Are Rarely De Novo. **2019**, 12, e002467	23

197	Desmoglein 2 mutation provokes skeletal muscle actin expression and accumulation at intercalated discs in murine hearts. **2019**, 132,	3
196	Catecholaminergic Polymorphic (Right) Ventricular Tachycardia?. **2019**, 5, 128-130	
195	Heart failure in patients with arrhythmogenic right ventricular cardiomyopathy: Genetic characteristics. **2019**, 286, 99-103	4
194	From Hypertrophy to Heart Failure: What Is New in Genetic Cardiomyopathies. **2019**, 16, 157-167	7
193	2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. **2019**, 16, e301-e372	247
192	Sudden death related cardiomyopathies - Arrhythmogenic right ventricular cardiomyopathy, arrhythmogenic cardiomyopathy, and exercise-induced cardiomyopathy. **2019**, 62, 217-226	7
191	The Netherlands Arrhythmogenic Cardiomyopathy Registry: design and status update. **2019**, 27, 480-486	13
190	Inherited cardiomyopathies. **2019**, 365, l1570	8
189	Risk score for the exclusion of arrhythmic events in arrhythmogenic right ventricular cardiomyopathy at first presentation. **2019**, 290, 100-105	4
188	Molecular mechanisms of arrhythmogenic cardiomyopathy. **2019**, 16, 519-537	77
187	Arrhythmogenic Right Ventricular Cardiomyopathy. **2019**, 410-419.e3	
186	Genotype-phenotype correlations in ARVC: Toward a precision medicine approach. **2019**, 286, 115-116	0
185	Heart failure in arrhythmogenic cardiomyopathy: is phenotypic variability just a matter of genetics?. **2019**, 21, 801-802	1
184	Arrhythmogenic cardiomyopathies (ACs): diagnosis, risk stratification and management. **2019**, 105, 1117-1128	11
183	Life-threatening arrhythmic presentation in patients with arrhythmogenic cardiomyopathy before and after entering the genomic era; a two-decade experience from a large volume center. **2019**, 279, 79-83	5
182	Prevalence and Electronic Health Record-Based Phenotype of Loss-of-Function Genetic Variants in Arrhythmogenic Right Ventricular Cardiomyopathy-Associated Genes. **2019**, 12, e002579	20
181	Plakophilin-2 Truncation Variants in Patients Clinically Diagnosed With Catecholaminergic Polymorphic Ventricular Tachycardia and Decedents With Exercise-Associated Autopsy Negative Sudden Unexplained Death in the Young. **2019**, 5, 120-127	24
180	A targeted next-generation gene panel reveals a novel heterozygous nonsense variant in the TP63 gene in patients with arrhythmogenic cardiomyopathy. **2019**, 16, 773-780	7

179	Arrhythmogenic Cardiomyopathy in 2018-2019: ARVC/ALVC or Both?. **2019**, 28, 164-177	35
178	Arrhythmogenic Right Ventricular Cardiomyopathy: Progress Toward Personalized Management. **2019**, 70, 1-18	9
177	Diagnostic and therapeutic strategies for arrhythmogenic right ventricular dysplasia/cardiomyopathy patient. **2019**, 21, 9-21	19
176	Arrhythmogenic right ventricular cardiomyopathy: evidence for progression increases. **2020**, 41, 1411-1413	7
175	Distal myopathy induced arrhythmogenic right ventricular cardiomyopathy in a pedigree carrying novel DSG2 null variant. **2020**, 298, 25-31	3
174	Catheter ablation of electrical storm in patients with arrhythmogenic right ventricular cardiomyopathy. **2020**, 17, 41-48	5
173	The merits of the ICD for inherited heart rhythm disorders: A critical re-appraisal. **2020**, 30, 415-421	1
172	Arrhythmogenic right ventricular cardiomyopathy. **2020**, 375-388	
171	Modeling Inherited Cardiomyopathies in Adult Zebrafish for Precision Medicine. **2020**, 11, 599244	6
170	The Novel Desmin Variant p.Leu115Ile Is Associated With a Unique Form of Biventricular Arrhythmogenic Cardiomyopathy. **2021**, 37, 857-866	7
169	Syncope in a 14yo female with ventricular tachycardia; an atypical etiology. **2021**, 45, 677.e5-677.e7	0
168	Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: Mechanisms and Management. **2020**, Volume 11, 19-29	1
167	Arrhythmogenic cardiomyopathy: An in-depth look at molecular mechanisms and clinical correlates. **2021**, 31, 395-402	9
166	Forty-six year old man with palpitations. **2020**, 106, 1235-1282	
165	Potential role of imaging markers in predicting future disease expression of arrhythmogenic cardiomyopathy. **2021**, 17, 647-654	5
164	Established and Emerging Mechanisms in the Pathogenesis of Arrhythmogenic Cardiomyopathy: A Multifaceted Disease. **2020**, 21,	9
163	Arrhythmogenic Right Ventricular Cardiomyopathy: An Exuberant Case Affecting Both Ventricles. **2020**, 13, e010243	1
162	Secondary findings in inherited heart conditions: a genotype-first feasibility study to assess phenotype, behavioural and psychosocial outcomes. **2020**, 28, 1486-1496	5

161	State of the Art Review on Genetics and Precision Medicine in Arrhythmogenic Cardiomyopathy. **2020**, 21,	9
160	Characteristics of Patients With Arrhythmogenic Left Ventricular Cardiomyopathy: Combining Genetic and Histopathologic Findings. **2020**, 13, e009005	5
159	Familial Arrhythmogenic Cardiomyopathy: Clinical Determinants of Phenotype Discordance and the Impact of Endurance Sports. **2020**, 9,	1
158	Arrhythmogenic right ventricular cardiomyopathy in patients with biallelic JUP-associated skin fragility. **2020**, 10, 21622	3
157	Development of an algorithm for automatic classification of right ventricle deformation patterns in arrhythmogenic right ventricular cardiomyopathy. **2020**, 37, 698-705	2
156	Desmosome-Dyad Crosstalk: An Arrhythmogenic Axis in Arrhythmogenic Right Ventricular Cardiomyopathy. **2020**, 141, 1494-1497	2
155	Parameter subset reduction for patient-specific modelling of arrhythmogenic cardiomyopathy-related mutation carriers in the CircAdapt model. **2020**, 378, 20190347	4
154	Genotype-Phenotype Correlation: A Triple DNA Mutational Event in a Boy Entering Sport Conveys an Additional Pathogenicity Risk. **2020**, 11,	10
153	Arrhythmogenic Cardiomyopathy: Molecular Insights for Improved Therapeutic Design. **2020**, 7,	6
152	Exercise restriction is protective for genotype-positive family members of arrhythmogenic right ventricular cardiomyopathy patients. **2020**, 22, 1270-1278	12
151	Right Heart Failure: Causes and Clinical Epidemiology. **2020**, 38, 175-183	4
150	Absence of ECG Task Force Criteria does not rule out structural changes in genotype positive ARVC patients. **2020**, 317, 152-158	2
149	Arrhythmogenic right ventricular cardiomyopathy : Evolving from unique clinical features to a´complex pathophysiological concept. **2020**, 45, 243-251	2
148	The role of genetics in cardiovascular disease: arrhythmogenic cardiomyopathy. **2020**, 41, 1393-1400	30
147	Natural History of Arrhythmogenic Cardiomyopathy. **2020**, 9,	19
146	Integrin 1D Deficiency-Mediated RyR2 Dysfunction Contributes to Catecholamine-Sensitive Ventricular Tachycardia in Arrhythmogenic Right Ventricular Cardiomyopathy. **2020**, 141, 1477-1493	14
145	Emerging concepts in arrhythmogenic dilated cardiomyopathy. **2021**, 26, 1219-1229	8
144	Predicting Heart Failure in Arrhythmogenic Right Ventricular Cardiomyopathy. **2020**, 9, e015702	1

143	Genetic basis and molecular biology of cardiac arrhythmias in cardiomyopathies. **2020**, 116, 1600-1619		15
142	Arrhythmogenic cardiomyopathy: pathogenesis, pro-arrhythmic remodelling, and novel approaches for risk stratification and therapy. **2020**, 116, 1571-1584		13
141	Dual-Organ Transplantation in a Woman With Right Ventricular Failure Secondary to Arrhythmogenic Right Ventricular Cardiomyopathy. **2020**, 2, 59-63		
140	Genetic variants of uncertain significance: How to match scientific rigour and standard of proof in sudden cardiac death?. **2020**, 45, 101712		12
139	Right Ventricular Strain Predicts Structural Disease Progression in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy. **2020**, 9, e015016		12
138	Epidemiology of the inherited cardiomyopathies. **2021**, 18, 22-36		32
137	Transcriptomic Coupling of PKP2 With Inflammatory and Immune Pathways Endogenous to Adult Cardiac Myocytes. **2020**, 11, 623190		6
136	Sex Differences in Right Ventricular Dysfunction: Insights From the Bench to Bedside. **2020**, 11, 623129		4
135	Two Novel Variants in Genes of Arrhythmogenic Right Ventricular Cardiomyopathy - a Case Report. **2021**, 28, 127-135		
134	Risk stratification and subclinical phenotyping of dilated and/or arrhythmogenic cardiomyopathy mutation-positive relatives: CVON eDETECT consortium. **2021**, 29, 301-308		
133	Deciphering DSC2 arrhythmogenic cardiomyopathy electrical instability: From ion channels to ECG and tailored drug therapy. **2021**, 11, e319		3
132	Exercise triggers CAPN1-mediated AIF truncation, inducing myocyte cell death in arrhythmogenic cardiomyopathy. **2021**, 13,		15
131	Rare Variants Associated with Arrhythmogenic Cardiomyopathy: Reclassification Five Years Later. **2021**, 11,		3
130	Impact of Genetic Variant Reassessment on the Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy Based on the 2010 Task Force Criteria. **2021**, 14, e003047		4
129	Electromechanical substrate characterization in arrhythmogenic cardiomyopathy using imaging-based patient-specific computer simulations. **2021**, 23, i153-i160		3
128	Arrhythmogenic Cardiomyopathy: Mechanisms, Genetics, and Their Clinical Implications. *Current Cardiovascular Risk Reports*, **2021**, 15, 1	0.9	1
127	Risk Stratification in Arrhythmogenic Right Ventricular Cardiomyopathy. **2021**, 10, 26-32		1
126	Update on the Diagnostic Pitfalls of Autopsy and Post-Mortem Genetic Testing in Cardiomyopathies. **2021**, 22,		5

125	Arrhythmogenic Right Ventricular Cardiomyopathy Presenting as Clinical Myocarditis in Women. **2021**, 145, 128-134	12
124	Cadherin 2-Related Arrhythmogenic Cardiomyopathy: Prevalence and Clinical Features. **2021**, 14, e003097	8
123	Clinical Findings and Diagnostic Yield of Arrhythmogenic Cardiomyopathy Through Genomic Screening of Pathogenic or Likely Pathogenic Desmosome Gene Variants. **2021**, 14, e003302	4
122	Genetics of Cardiomyopathy.	
121	Actionable secondary findings in arrhythmogenic right ventricle cardiomyopathy genes: impact and challenge of genetic counseling. **2021**, 11, 637-649	0
120	Clinical Insights Into Heritable Cardiomyopathies. **2021**, 12, 663450	3
119	An actuarial model of arrhythmogenic right ventricular cardiomyopathy and life insurance. 1-21	
118	Arrhythmogenic Left Ventricular Cardiomyopathy: Genotype-Phenotype Correlations and New Diagnostic Criteria. **2021**, 10,	5
117	Peeking Beyond Strain's Peak: Regional Strain Patterns and Dispersion in Arrhythmogenic Right Ventricular Cardiomyopathy. **2021**, 14, 911-914	1
116	Contemporary and Future Approaches to´Precision Medicine in Inherited´Cardiomyopathies: JACC Focus Seminar 3/5. **2021**, 77, 2551-2572	4
115	Pregnancy in arrhythmogenic cardiomyopathy. **2021**, 32, 186-198	0
114	Right Ventricular Functional´Abnormalities in Arrhythmogenic Cardiomyopathy: Association With Life-Threatening Ventricular Arrhythmias. **2021**, 14, 900-910	9
113	State-of-the-art narrative review: multimodality imaging in electrophysiology and cardiac device therapies. **2021**, 11, 881-895	1
112	Diagnostic yield of targeted next generation sequencing in 2002 Dutch cardiomyopathy patients. **2021**, 332, 99-104	2
111	Sporadic and rapidly progressive arrhythmogenic right ventricular cardiomyopathy in a 12-year-old boy who was diagnosed with epilepsy. **2021**, 2021, omab046	0
110	The EP300/TP53 pathway, a suppressor of the Hippo and canonical WNT pathways, is activated in human hearts with arrhythmogenic cardiomyopathy in the absence of overt heart failure. **2021**,	2
109	Beneficial effect of voluntary physical exercise in Plakophilin2 transgenic mice. **2021**, 16, e0252649	0
108	Pathogenic variants in plakophilin-2 gene (PKP2) are associated with better survival in arrhythmogenic right ventricular cardiomyopathy. **2021**, 62, 613-620	2

107	International Evidence Based Reappraisal of Genes Associated With Arrhythmogenic Right Ventricular Cardiomyopathy Using the Clinical Genome Resource Framework. **2021**, 14, e003273	21
106	Cardiomyopathies: An Overview. **2021**, 22,	6
105	Altered Electrical, Biomolecular, and Immunologic Phenotypes in a Novel Patient-Derived Stem Cell Model of Desmoglein-2 Mutant ARVC. **2021**, 10,	2
104	Anatomical-MRI Correlations in Adults and Children with Arrhythmogenic Right Ventricular Cardiomyopathy. **2021**, 11,	
103	Effect of preload reducing therapy on right ventricular size and function in patients with arrhythmogenic right ventricular cardiomyopathy. **2021**, 18, 1186-1191	3
102	Genotype-phenotype correlation in arrhythmogenic right ventricular cardiomyopathy-risk of arrhythmias and heart failure. **2021**,	1
101	Outcomes after catheter ablation of ventricular tachycardia without implantable cardioverter-defibrillator in selected patients with arrhythmogenic right ventricular cardiomyopathy. **2021**, 23, 1428-1436	0
100	Peculiar Aspects of Patients with Inherited Arrhythmias during the COVID-19 Pandemic. **2021**, 117, 394-403	0
99	Clinical characteristics and risk stratification of desmoplakin cardiomyopathy. **2021**,	6
98	Desmoplakin cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy: two distinct forms of cardiomyopathy?. **2021**,	
97	Epicardial differentiation drives fibro-fatty remodeling in arrhythmogenic cardiomyopathy. **2021**, 13, eabf2750	3
96	Contribution of concomitant myocarditis to the development of various clinical types of arrhythmogenic right ventricular cardiomyopathy. **2021**, 20, 2781	1
95	Running the Risk: Exercise and Arrhythmogenic Cardiomyopathy.. **2021**, 23, 1	
94	Comparing clinical performance of current implantable cardioverter-defibrillator implantation recommendations in arrhythmogenic right ventricular cardiomyopathy. **2021**,	1
93	The clinical utility of pediatric cardiomyopathy genetic testing: From diagnosis to a precision medicine-based approach to care. **2021**, 62, 101413-101413	0
92	Uncertainty Quantification of Regional Cardiac Tissue Properties in Arrhythmogenic Cardiomyopathy Using Adaptive Multiple Importance Sampling. **2021**, 12, 738926	1
91	Molecular autopsy and subsequent functional analysis reveal de novo DSG2 mutation as cause of sudden death. **2021**, 64, 104322	
90	Evaluation and monitoring of patients with cardiomyopathies (including myocardial infiltration). **2022**, 77-104.e5	

89	Genetic Restrictive Cardiomyopathy: Causes and Consequences-An Integrative Approach. **2021**, 22,	8
88	Inherited cardiomyopathies. **2021**, 277-290	
87	Electrocardiographic features of arrhythmogenic right ventricular cardiomyopathy in school-aged children. **2021**, 36, 863-873	
86	Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. **2020**, 41, 1414-1429	110
85	Appropriate and Inappropriate Implantable Cardioverter Defibrillators Therapies in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia Patients. **2018**, 9, 204-214	5
84	Nature and Nurture in Arrhythmogenic Right Ventricular Cardiomyopathy - A Clinical Perspective. **2015**, 4, 156-62	2
83	Wnt/Ecatenin pathway in arrhythmogenic cardiomyopathy. **2017**, 8, 60640-60655	34
82	Practical Aspects in Genetic Testing for Cardiomyopathies and Channelopathies. **2019**, 40, 187-200	4
81	Circulation and Contacts in Sixteenth Century New Cartography: Spain, Portugal and Italy. **2021**, 10, e015	
80	Heart Failure in Patients with Arrhythmogenic Cardiomyopathy. **2021**, 10,	0
79	How exercise can deteriorate the clinical course of an ARVC patient: a case report. **2021**, 5, ytab417	0
78	Diagnostic Evaluation of Children with Known or Suspected ARVC/D. **2016**, 105-113	
77	Arrhythmogenic Cardiomyopathy. **2016**, 91-111	
76	Arrhythmogenic Cardiomyopathy. **2018**, 6-9	
75	Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death Guideline Update. **2020**, 31, 221-227	0
74	SARS-CoV-2 protein Nsp1 alters actomyosin cytoskeleton and phenocopies arrhythmogenic cardiomyopathy-related PKP2 mutant.	
73	Arrhythmogenic right ventricular cardiomyopathy in the pediatric population. **2022**, 37, 99-108	4
72	Arrhythmogenic Right Ventricular Cardiomyopathy. **2020**, 791-810	

71	Arrhythmogenic Cardiomyopathy. **2020**, 99-114	
70	Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC). **2020**, 93-123	
69	Genetic and Molecular Basis of Cardiac Arrhythmias. **2020**, 75-96	
68	CLINICAL CASE OF NON-COMPACTION CARDIOMYOPATHY IN A PATIENT WITH PKP2 GENE MUTATION. **2020**, 106-111	
67	Arrhythmogenic right ventricular cardiomyopathy in Boxer dogs: the diagnosis as a link to the human disease. **2017**, 36, 135-150	5
66	Identification of Disrupted Myocardial Calcium Homeostasis as Proarrhythmic Trigger in Arrhythmogenic Cardiomyopathy. **2021**, 12, 732573	
65	In silico Identification of Disrupted Myocardial Calcium Homeostasis as Proarrhythmic Trigger in Arrhythmogenic Cardiomyopathy. **2021**, 12, 732573	1
64	MicroRNAs: From Junk RNA to Life Regulators and Their Role in Cardiovascular Disease. **2021**, 11, 230-254	
63	Clinical and genetic features of arrhythmogenic cardiomyopathy: the electrophysiology perspective. **2021**, 101463	
62	Spectrum of desmosomal gene variations in patients with arrhythmogenic right ventricular cardiomyopathy. **2021**, 26, 4692	0
61	The genetic basis of sudden death in young people - Cardiac and non-cardiac. **2021**, 810, 146067	
60	Arrhythmogenic Right Ventricular Cardiomyopathy in Pediatric Patients: An Important but Underrecognized Clinical Entity.. **2021**, 9, 750916	2
59	Cardiovascular Characteristics of Patients with Genetic Variation in Desmoplakin ().. **2022**, 12, 24-36	2
58	Integrating Exercise Into Personalized Ventricular Arrhythmia Risk Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy.. **2022**, CIRCEP121010221	0
57	Penetrance and disease expression of (likely) pathogenic variants associated with inherited cardiomyopathies in the general population.	
56	Role of genetic testing in cardiomyopathies: □primer for cardiologists.. **2022**, 14, 29-39	1
55	Arrhythmogenic Right Ventricular Cardiomyopathy in an Older Private Pilot.. **2022**, 93, 111-115	
54	Multimodality Imaging in Arrhythmogenic Right Ventricular Cardiomyopathy.. **2022**, CIRCIMAGING121013725	0

53	Arrhythmogenic Right Ventricular Cardiomyopathy and Differential Diagnosis with Diseases Mimicking Its Phenotypes.. **2022**, 11,	3
52	Clinical Characteristics and Follow-Up of Pediatric-Onset Arrhythmogenic Right Ventricular Cardiomyopathy.. **2022**, 8, 306-318	2
51	Atomic Force Microscopy (AFM) Applications in Arrhythmogenic Cardiomyopathy.. **2022**, 23,	2
50	Arrhythmogenic Right Ventricular Cardiomyopathy: Overview and Case Study.. **2022**, 33, 14-22	
49	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases.. **2022**,	5
48	Elucidating arrhythmogenic right ventricular cardiomyopathy with stem cells.. **2022**,	
47	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases.. **2022**,	6
46	Practitioners' Confidence and Desires for Education in Cardiovascular and Sudden Cardiac Death Genetics.. **2022**, e023763	
45	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases.	2
44	Myocarditis or inherited disease? - The multifaceted presentation of arrhythmogenic cardiomyopathy.. **2022**, 827, 146470	0
43	Ventricular arrhythmia management in patients with genetic cardiomyopathies.. **2021**, 2, 819-831	
42	Histopathological Features and Protein Markers of Arrhythmogenic Cardiomyopathy.. **2021**, 8, 746321	1
41	Heart transplantation strategies in arrhythmogenic right ventricular cardiomyopathy: a tertiary ARVC centre experience.. **2021**,	1
40	Pathogenesis, Diagnosis and Risk Stratification in Arrhythmogenic Cardiomyopathy. **2021**, 11, 263-289	
39	The Female Athlete's Heart: Overview and Management of Cardiovascular Diseases.. **2021**, 16, e47	2
38	Fibro-fatty remodelling in arrhythmogenic cardiomyopathy.. **2022**, 117, 22	0
37	Arrhythmogenic Right Ventricular Cardiomyopathy.. **2022**, 8, 533-553	1
36	Table_1.XLS. **2018**,	

35	New Variant in Placophilin-2 Gene Causing Arrhythmogenic Myocardiopathy. **2022**, 13, 782	
34	Arrhythmogenic Right Ventricular Dysplasia (ARVD) With Protein Plakophilin-2 Mutation. **2022**,	
33	Exercise Causes Arrhythmogenic Remodeling of Intracellular Calcium Dynamics in Plakophilin-2-Deficient Hearts.. **2022**,	2
32	Population Prevalence of Premature Truncating Variants in Plakophilin-2 and Association With Arrhythmogenic Right Ventricular Cardiomyopathy: a UK Biobank Analysis.. **2022**, 101161CIRCGEN121003507	0
31	Arrhythmogenic Right Ventricular Cardiomyopathy Prevalence and Arrhythmic Outcomes in At-Risk Family Members: A Systematic Review and Meta-Analysis.. **2022**, 101161CIRCGEN121003530	0
30	Device-measured physical activity, sedentary time, and sleep in patients with arrhythmogenic cardiomyopathy: descriptive values and stability over 30 measurement days.	0
29	Arrhythmias as Presentation of Genetic Cardiomyopathy. **2022**, 130, 1698-1722	0
28	The value of genetic testing in the diagnosis and risk stratification of arrhythmogenic right ventricular cardiomyopathy. **2022**,	
27	Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator.	1
26	Burden of rare variants in arrhythmogenic cardiomyopathy with right dominant form associated genes provides new insights for molecular diagnosis and clinical management..	0
25	Family History and Warning Symptoms Precede Sudden Cardiac Death in Arrhythmogenic Right Ventricular Cardiomyopathy (from a Nationwide Study in Sweden). **2022**,	
24	A rare case of arrhythmogenic right ventricular cardiomyopathy associated with LAMA2 mutation: A case report and literature review. 9,	0
23	Novel Risk Prediction Model to Determine Adverse Heart Failure Outcomes in Arrhythmogenic Right Ventricular Cardiomyopathy. **2022**, 11,	0
22	Sex Differences in Cardiomyopathy. *Current Cardiovascular Risk Reports*,	0.9
21	Spectrum of Rare and Common Genetic Variants in Arrhythmogenic Cardiomyopathy Patients. **2022**, 12, 1043	
20	Genetic testing for cardiomyopathies: when science and health policies join in personalizing cardiovascular prevention.	
19	Loss of Nuclear Envelope Integrity and Increased Oxidant Production Cause DNA Damage in Adult Hearts Deficient in PKP2: A Molecular Substrate of ARVC. **2022**, 146, 851-867	2
18	The Athlete's Heart: Challenges and Controversies. **2022**, 80, 1346-1362	0

17	Humanized Dsp ACM Mouse Model Displays Stress-Induced Cardiac Electrical and Structural Phenotypes. **2022**, 11, 3049	1
16	Genotype–Phenotype Correlates in Arrhythmogenic Cardiomyopathies.	0
15	Prevalence and Phenotypic Burden of Monogenic Arrhythmias Using Integration of Electronic Health Records With Genetics.	0
14	Genetics and Genomics of Congenital and Acquired Cardiovascular Disease. **2021**, 1-41	0
13	Arrhythmogenic Cardiomyopathy: A Review of a Rare Case of Biventricular Phenotype. **2022**,	0
12	Prevalence and Disease Expression of Pathogenic and Likely Pathogenic Variants Associated With Inherited Cardiomyopathies in the General Population.	0
11	Exercise After Acute Myocarditis. **2023**, 41, 107-115	0
10	Clinical characteristics of various arrhythmogenic cardiomyopathy phenotypes in the pediatric population: a systematic review and meta-analysis. **2022**, 27, 5146	0
9	Clinical and echocardiographic evolution of patients with arrhythmogenic cardiomyopathy before heart transplantation.	0
8	Clinical course of arrhythmogenic right ventricular cardiomyopathy with end-stage heart failure and outcome after heart transplantation. **2022**,	0
7	Modeling incomplete penetrance in arrhythmogenic cardiomyopathy by human induced pluripotent stem cell derived cardiomyocytes. **2023**, 21, 1759-1773	0
6	Catalytic antibodies in arrhythmogenic cardiomyopathy patients cleave desmoglein 2 and N-cadherin and impair cardiomyocyte cohesion.	0
5	A Crossroads Junction That Leads to Heart Failure (Arrhythmogenic Cardiomyopathy): Hope for Future Therapeutics. **2023**, 13, 31-32	0
4	Cardiomyopathies in children: An overview. **2023**,	0
3	Advances in Ion Channel, Non-Desmosomal Variants and Autophagic Mechanisms Implicated in Arrhythmogenic Cardiomyopathy. **2023**, 45, 2186-2200	0
2	Connexin hemichannels as candidate targets for cardioprotective and anti-arrhythmic treatments. **2023**, 133,	0
1	Disease modeling of desmosome-related cardiomyopathy using induced pluripotent stem cell-derived cardiomyocytes. 15, 71-82	0